VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $5.75 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 56.25% from the company’s current price.

Separately, BTIG Research initiated coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective on the stock.

VYNE Therapeutics Stock Up 6.4 %

NASDAQ VYNE traded up $0.22 during mid-day trading on Monday, hitting $3.68. The stock had a trading volume of 108,679 shares, compared to its average volume of 90,237. The company has a 50 day simple moving average of $2.87 and a 200 day simple moving average of $2.26. The company has a market cap of $54.28 million, a price-to-earnings ratio of -4.28 and a beta of 1.30. VYNE Therapeutics has a 52-week low of $1.57 and a 52-week high of $3.84.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises approximately 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics as of its most recent SEC filing. 83.78% of the stock is owned by institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.